[1]
|
I. B. Ghorbela, S. C. Kanouna, A D. Kallela, A. B. Belaida, F. Azourya, S. Heymanna, et al., “Cancer du Sein Sans Atteinte Ganglionnaire Axillaire,” Cancer/Radiothérapie, Vol. 14, Suppl. 1, 2010, pp. S127-S135.
|
[2]
|
B. Trétarre, A. V. Guizard and D. Fontaine, “Cancer du Sein Chez la Femme: Incidence et Mortalité, France 2000,” BEH, Vol. 44, 2004, pp. 209-210.
|
[3]
|
T. Akiyama, C. Sudo, H. Ogawara, et al., “The Product of the Human c-erbB-2 Gene: A 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity,” Science, Vol. 232, No. 4758, 1986, pp. 1644-1646. doi:10.1126/science.3012781
|
[4]
|
D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, et al., “Studies of the HER-2/Neu Proto-Oncogene in Human Breast and Ovarian Cancer,” Science, Vol. 244, No. 4905, 1989, pp. 707-712. doi:10.1126/science.2470152
|
[5]
|
G. Pauletti, W. Godolphin, M. F. Press and D. J. Slamon, “Detection and Quantitation of HER-2/Neu Gene Amplification in Human Breast Cancer Archival Material Using Fluorescence in Situ Hybridization,” Oncogene, Vol. 13, No. 1, 1996, pp. 63-72.
|
[6]
|
T. Rajkumar and W. J. Gullick, “The Type I Growth Factor Receptors in Human Breast Cancer,” Breast Cancer Research and Treatment, Vol. 29, No. 1, 1994, pp. 3-9. doi:10.1007/BF00666177
|
[7]
|
C. R. De Potter and A. M. Schelfhout, “The Neu-Protein and Breast Cancer,” Virchows Arch, Vol. 426, No. 2, 1995, pp. 107-115.
|
[8]
|
G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, R. Seshadri and D. J. Slamon, “Assessment of Methods for Tissue-Based Detection of the HER-2/Neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence in Situ Hybridization and Immunohistochemistry,” Journal of Clinical Oncology, Vol. 18, No. 21, 2000, pp. 3651-3664.
|
[9]
|
D. Varshney, Y. Y. Zhou, S. A. Geller and R. Alsabeh, “Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay,” American Journal of Clinical Pathology, Vol. 121, No. 1, 2004, pp. 70-77. doi:10.1309/FUQH92B039025LHG
|
[10]
|
C. C. Benz, G. K. Scott, J. C. Sarup, et al., “Estrogen-Dependent, Tamoxifen-Resistant Tumorigenic Growth of MCF-7 Cells Transfected with HER2/Neu,” Breast Cancer Research and Treatment, Vol. 24, No. 2, 1993, pp. 85-95. doi:10.1007/BF01961241
|
[11]
|
D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich and W. L. McGuire, “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/Neu Oncogene,” Science, Vol. 235, No. 4785, 1987, pp. 177-182. doi:10.1126/science.3798106
|
[12]
|
B. A. Gusterson, R. D. Gelber, A. Goldhirsch, et al., “Prognostic Importance of c-erbB-2 Expression in Breast Cancer,” Journal of Clinical Oncology, Vol. 10, No. 7, 1992, pp. 1049-1056.
|
[13]
|
P. Kronqvist, T. Kuopio, M. Nykanen, et al., “Predicting Aggressive Outcome in T1N0M0 Breast Cancer,” British Journal of Cancer, Vol. 91, No. 2, 2004, pp. 277-281.
|
[14]
|
S. B. Bull, H. Ozcelik, D. Pinnaduwage, et al., “The Combination of p53 Mutation and Neu/erbB-2 Amplification Is Associated with Poor Survival in Nodenegative Breast Cancer,” Journal of Clinical Oncology, Vol. 22, No. 1, 2004, pp. 86-96. doi:10.1200/JCO.2004.09.128
|
[15]
|
F. Tavassoli and P. Devilee, “World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs,” IARC Press, Lyon, 2003.
|
[16]
|
E. W. Elston and I. O. Ellis, “Method for Grading Breast Cancer,” Journal of Clinical Pathology, Vol. 46, No. 2, 1993, pp. 189-190.
|
[17]
|
D. C. Allred, J. M. Harvey, M. Berardo and G. M. Clark, “Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis,” Modern Pathology, Vol. 11, No. 2, 1998, pp. 155-168.
|
[18]
|
S. J. Schnitt, “Traditional and Newer Pathologic Factors,” Journal of the National Cancer Institute. Monographs, Vol. 2001, No. 30, 2001, pp. 22-26. doi:10.1093/oxfordjournals.jncimonographs.a003456
|
[19]
|
D. Cameron and R. Bell, “Optimizing Treatment for Patients with Breast Cancer,” Seminars in Oncology, Vol. 31, No. 10, 2004, pp. 4-5. doi:10.1053/j.seminoncol.2004.07.015
|
[20]
|
L. Ayadi, A. Khabir, H. Amouri, S. Karray, A. Dammak, M. Guermazi and T. Boudawara, “Correlation of HER-2 Over-Expression with Clinico-Pathological Parameters in Tunisian Breast Carcinoma,” World Journal of Surgical Oncology, Vol. 6, 2008, p. 112. doi:10.1186/1477-7819-6-112
|
[21]
|
T. El-AHelal, A. Khalifa and A. S. Kamel, “Immunohistochemical Expression of p53 and cerbB2 Proteins in Breast Cancer in Egypt,” Anticancer Research, 20, 3B, 2000, pp. 2145-2150.
|
[22]
|
S. Taucher, M. Rudas, R. M. Mader, M. Gnant, P. Dubsky, T. Bachleitner, et al., “Do We Need HER-2/Neu Testing for All Patients with Primary Breast Carcinoma?” Cancer, Vol. 98, No. 12, 2003, pp. 2547-2553. doi:10.1002/cncr.11828
|
[23]
|
S. Eppenberger-Castori, D. H. Moore Jr., A. D. Thor, S. M. Edgerton, W. Kueng, U. Eppenberger and C. C. Benz, “Age-Associated Biomarker Profiles of Human Breast Cancer,” The International Journal of Biochemistry & Cell Biology, Vol. 34, No. 11, 2002, pp. 1318-1330. doi:10.1016/S1357-2725(02)00052-3
|
[24]
|
N. M. Almasri and M. Al Hamad, “Immunohistochemical Evaluation of Human Epidermal Growth Factor Receptor 2 and Estrogen and Progesterone Receptors in Breast Carcinoma in Jordan,” Breast Cancer Research, Vol. 7, No. 5, 2005, pp. R598-R604. doi:10.1186/bcr1200
|
[25]
|
H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limbergen, et al., “Hormone Receptors Do Not Predict the HER2/Neu Status in All Age Groups of Women with an Operable Breast Cancer,” Annals of Oncology, Vol. 16, No. 11, 2005, pp. 1755-1761. doi:10.1093/annonc/mdi364
|
[26]
|
B. K. Seo, E. D. Pisano, C M. Kusimak, M. Koomen, D. Pavic, Y. Lee, E. B. Cole and J. Y. Lee, “Correlation of HER-2/Neu Overexpression with Mammography and Age Distribution in Primary Breast Carcinomas,” Academic Radiology, Vol. 13, No. 10, 2006, pp. 1211-1218. doi:10.1016/j.acra.2006.06.015
|
[27]
|
J. M. Bhatavdekar, D. D. Patel, N. G. Shah, H. H. Vora, T. P. Suthar, P. R. Chikhlikar, et al., “Prognostic Significance of Immunohistochemically Localized Biomarkers in Stage II and Stage III Breast Cancer: A Multivariate Analysis,” Annals of Surgical Oncology, Vol. 7, No. 4, 2000, pp. 305-311. doi:10.1007/s10434-000-0305-5
|
[28]
|
T. Ivkovic-Kapicl, S. Knezevic-Usaj, D. Djilas-Ivanovic and M. Panjkovic, “Correlation of HER-2/Neu Protein Overexpression with Other Prognostic and Predictive Factors in Invasive Ductal Breast Cancer,” Anticancer Research, Vol. 21, No. 4, 2007, pp. 673-678
|
[29]
|
R. Prati, S. K. Apple, J. He, J. A. Gornbei and H. R. Chanh, “Histopathologic Characteristics Predicting HER-2/Neu Amplification in Breast Cancer,” Breast Journal, Vol. 11, No. 6, 2005, pp. 433-439. doi:10.1111/j.1075-122X.2005.00125.x
|
[30]
|
H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limberger, P. Berteloot, F. Amant, I. Vergote and M. R. Christiaens, “Association between Tumour Characteristics and HER-2/Neu by Immunohistochemistry in 1362 Women with Primary Operable Breast Cancer,” Journal of Clinical Pathology, Vol. 58, No. 6, 2005, pp. 611-616. doi:10.1136/jcp.2004.022772
|
[31]
|
S. Paik, J. Brayant, C. Park, B. Fisher, E. Tan-Chiu, D. Hyams, et al., “ErbB-2 and Response to Doxorubicin in Patients with Axillary Lymph-Node Positive, Hormone Receptor-Negative Breast Cancer,” Journal of the National Cancer Institute, Vol. 90, No. 18, 1998, pp. 1361-1370. doi:10.1093/jnci/90.18.1361
|
[32]
|
R. Ariga, A. Zarif, J. Korasick, V. Reddy, K. Siziopikou and P. Gattuso, “Correlation of Her 2/Neu Gene Amplification with Other Prognostic and Predictive Factors in Female Breast Carcinoma,” Breast Journal, Vol. 11, No. 4, 2005, pp. 278-280. doi:10.1111/j.1075-122x.2005.21463.x
|
[33]
|
E. R. Hoff, R. R. Tubbs, J. L. Myles and G. W. Procop, “HER-2/Neu Amplification in Breast Cancer. Stratification by Tumor Type and Grade,” Am Journal of Clinical Pathology, Vol. 117, No. 6, 2002, pp. 916-921. doi:10.1309/4NTU-N6K4-F8JF-EWRX
|
[34]
|
I. L. Andrulis, S. B. Bull, M. E. Blackstein, D. Sutherland, C. Mak, S. Sidlofsky, et al., Toronto Breast Cancer Study Group, “Neu/erbB-2 Amplification Identifies a Poor-Prognosis Group of Women with Node-Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 16, No. 4, 1998, pp. 1340-1349.
|
[35]
|
A. Traina, B. Agostara, L. Marasà, M. Calabrò, M. Zarcone and G. Carruba, “HER2/Neu Expression in Relation to Clinicopathologic Features of Breast Cancer Patients,” Annals of the New York Academy of Sciences, Vol. 1089, 2006, pp. 159-167. doi:10.1196/annals.1386.029
|
[36]
|
A Harlozinska, J. K. Bar, R. Wenderski and M. Bebenek, Association with Tumor Phenotypes, “Relationship between c-erbB-2 Oncoprotein, Epidermal Growth Factor Receptor, and Estrogen Receptor Expression in Patients with Ductal Breast Carcinoma,” In Vivo, Vol. 10, No. 2, 1996, pp. 217-222.
|
[37]
|
S. A. Aziz, S. Pervez, S. Khan, N. Kayani, S. I. Azam and M. H. Rahbar, “Significance of Immunohistochemical Pattern for Prognosis in Human Breast Cancer,” Pathology & Oncology Research, Vol. 7, No. 3, 2001, pp. 190-196. doi:10.1007/BF03032348
|
[38]
|
S. Kariya, Y. Ogawa, A. Nishioka, T. Moriki, T. Ohnishi, S. Ito, Y. Murata and S. Yoshida, “Relationship between Hormonal Receptors, HER-2, p53 Protein, bcl-2, and MIB-1 Status and the Antitumor Effects Of Neoadjuvant Anthracycline-Based Chemotherapy in Invasive Breast Cancer Patients,” Radiation Medicine, Vol. 23, No. 3, 2005, pp. 189-194.
|
[39]
|
A. E. Pinto, S. Andre, T. Pareira, S. Nobrega and J. Soares, “C-erbB-2 Oncoprotein Overexpression Identifies a Subgroup of Estrogen Receptor Positive (ER+) Breast Cancer Patients with Poor Prognosis,” Annals of Oncology, Vol. 12, No. 4, 2001, pp. 525-33. doi:10.1023/A:1011163211802
|
[40]
|
S. Kaptain, L. K. Tan and B. Chen, “Her-2/Neu and Breast Cancer,” Diagnostic Molecular Pathology, Vol. 10, 3, 2001, pp. 139-152. doi:10.1097/00019606-200109000-00001
|
[41]
|
S. Selvarajan, K. Y. Wong, K. S. Khoo, B. H. Bay and P. H. Tan, “Overexpression of c-erbB2 Correlates with Nu- clear Morphometry and Prognosis in Breast Carcinoma in Asian women,” Pathology, Vol. 38, No. 6, 2006, pp. 528-533. doi:10.1080/00313020601024060
|
[42]
|
S. Taucher, M. Rudas, R. M. Mader, M. Gnant, P. Dubsky, T. Bachleitner and S. Roka, “Do We Need HER-2/Neu Testing for All Patients with Primary Breast Carcinoma?” Cancer, Vol. 98, No. 12, 2003, pp. 2547-2553. doi:10.1002/cncr.11828
|